Express Scripts
Express Scripts is the largest U.S. pharmacy benefit manager (PBM) by claims volume — Drug Channels Institute ranked it No. 1 in 2024 and 2025 — and one of the three PBMs that together process about 80% of all prescription claims. Owned by The Cigna Group since 2018, it manages drug formularies, negotiates manufacturer rebates, operates mail-order and specialty pharmacies, and administers prescription benefits for over 100 million people. In February 2026, Express Scripts reached a landmark FTC settlement requiring structural reforms to its rebate and formulary practices.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-09-25. Score revised 2026-09-25: 74 → 71.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Express Scripts began in St. Louis as a small joint-venture PBM in a fragmented, competitive market, was bought by New York Life in 1989 and went public on NASDAQ in 1992. The record shows no documented enforcement actions, major acquisitions or pricing controversies from this period; the business was a modest claims processor.
The $445 million ValueRx purchase in April 1998 and the $700 million Diversified Pharmaceutical Services deal in 1999 made Express Scripts a top-three PBM, and the 2009 NextRx acquisition added WellPoint's PBM book under a 10-year contract. New York's 2004 lawsuit alleged retained rebates, inflated generic spreads and undisclosed drug switching, practices settled for $27 million in New York and $9.3 million with 28 states and D.C. in 2008. The era ended with the Medco merger.
The $29.1 billion Medco acquisition, cleared on April 2, 2012 over a dissent warning of a 'merger to duopoly', made Express Scripts the largest PBM. It began excluding brand drugs from its national formulary in 2014, cut about 2,290 jobs that year, and saw retroactive DIR clawbacks, Anthem's $15 billion overcharging suit and independent pharmacies' mail-order poaching suit. Accredo paid $60 million in 2015 over Novartis kickbacks. The era closed with Cigna's acquisition.
Cigna's $67 billion acquisition closed on December 20, 2018, joining the PBM with an insurer and later rebranding the unit as Evernorth. Anthem left in 2019, Express Scripts set up the Swiss GPO Ascent and began a reimbursement collaboration with Prime Therapeutics, and Axios exposed pharmacy performance clawbacks, while the $25 insulin cap was a genuine patient improvement. By 2022 J&J had sued over the SaveOnSP copay maximizer run with Express Scripts, and the FTC opened its PBM inquiry.
On October 24, 2022 nearly 15,000 pharmacies left the TRICARE network after rejecting Express Scripts' below-cost reimbursement terms, leaving about 400,000 beneficiaries without their pharmacy. Ohio sued over the Prime collaboration, pharmacies filed a price-fixing class action, and a federal audit found $44.9 million in overcharges to a postal workers' plan. Cigna answered its failed Humana talks with a $10 billion buyback authorization and about $7 billion of 2024 repurchases, and Express Scripts' president chaired the PBM lobby.
The FTC sued Express Scripts and the other two largest PBMs on September 20, 2024 over rebate practices that allegedly inflated insulin prices; Express Scripts had sued the agency days earlier over its report and later challenged the case's constitutionality. Kentucky, Michigan, West Virginia and Philadelphia sued, an arbitrator found Prime's collaboration with it was price-fixing, and it led the suit that blocked Arkansas's ban on PBM-owned pharmacies. In late 2025 it announced a rebate-free model while doubling 2026 formulary exclusions.
The February 4, 2026 FTC settlement commits Express Scripts to stop preferring high-list-price drugs, offer a delinked, net-price standard benefit, move pharmacies to cost-plus pay and reshore Ascent, mostly by 2027-2028 and without a penalty. Days later Cigna cut 2,000 jobs; buybacks then slowed sharply and a new CEO took over in July. Meanwhile it sued Tennessee to keep owning pharmacies, faced a racketeering class action over Ascent, new Florida and Louisiana price-fixing suits and Senate scrutiny of its TRICARE role.
Alternatives
Mark Cuban's direct-to-consumer mail-order pharmacy, a public benefit corporation that prices each drug at its cost plus a 15% markup, a $5 pharmacy fee and a shipping fee, bypassing PBMs such as Express Scripts. For many common generics, and some specialty generics such as imatinib, the cash price is far below list and often below a plan copay. Have your prescription sent there and pay directly. The catch: the catalog is mostly generics with only a few brand-name drugs, everything ships by mail, and purchases are cash outside your insurance benefit.
Free discount card and price-comparison app accepted at more than 70,000 U.S. pharmacies, which can undercut your Express Scripts copay on many generics; useful if you are being steered to Express Scripts' mail-order pharmacy. Check it before each fill and show the coupon at the counter. The catch: GoodRx shared users' health data with Facebook and Google (a $1.5 million FTC penalty in 2023), its coupon prices run through PBM partners including Express Scripts, and independent pharmacies' antitrust suits allege that arrangement suppressed their generic reimbursements. Cash-coupon fills usually sit outside your insurance benefit.
For employers and plan sponsors, not individual patients: a pass-through PBM owned by the nonprofit SSM Health with a Costco minority stake. It says it passes 100% of manufacturer rebates and network discounts to clients, and from 2026 it offers Costco's cost-plus pricing at retail and mail order. Switching still means a multi-year PBM contract and formulary disruption, and Navitus is among the PBMs named with GoodRx in independent pharmacies' reimbursement price-fixing suits.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (77 events)
Express Scripts founded as joint venture PBM
Express Scripts was created in late 1986 as a joint venture between GenCare Health Systems (the umbrella for the Sanus Corp. Health Systems HMO plans) and Medicare-Glaser, a St. Louis pharmacy chain operating nearly 90 stores, to provide mail-order prescription and claims processing services. The new company entered a nascent PBM industry that would later come to dominate pharmaceutical distribution.
New York Life Insurance acquires Express Scripts
New York Life Insurance Company purchased Express Scripts, providing capital for growth. NYLife Healthcare Management, a subsidiary, would retain controlling interest through a dual-class share structure even after the company went public in 1992.
Express Scripts IPO on NASDAQ raises $28 million
Express Scripts went public on the NASDAQ exchange, raising more than $28 million. New York Life retained controlling interest through Class B shares with 10 votes per share, while public Class A shares had one vote each. Stock rose from $13 IPO price to $35.25 early in 1993.
Express Scripts acquires ValueRx for $445 million
Express Scripts agreed in February 1998 to buy ValueRx, the PBM business of Columbia/HCA Healthcare Corp., for approximately $445 million in cash, and completed the deal in April 1998, creating the largest U.S. PBM independent of a drug manufacturer. The acquisition expanded claims processing and formulary management scale significantly, giving the combined entity greater leverage over pharmacy reimbursement rates and employer plan negotiations.
Diversified Pharmaceutical Services acquired for $700 million
Express Scripts purchased Diversified Pharmaceutical Services from SmithKline Beecham Corp for $700 million in cash in April 1999. The deal secured Express Scripts' position as the third-largest PBM overall in the U.S., managing nearly $10 billion in drug spending.
NY Attorney General Spitzer sues Express Scripts over retained rebates
New York Attorney General Eliot Spitzer sued Express Scripts on behalf of the Empire Plan, the state's largest employee health plan, alleging the PBM diverted millions of dollars in manufacturer rebates by disguising them as 'administrative' and other fees, inflated generic drug costs to widen its spread, sold plan data without permission, and deceived physicians into switching patients to drugs whose makers paid Express Scripts. Express Scripts and CIGNA settled the case in July 2008 for $27 million without admitting wrongdoing.
George Paz becomes CEO, accelerating growth strategy
George Paz succeeded Barrett Toan as CEO of Express Scripts in April 2005. Under Paz's leadership over the next 11 years, annual revenue grew from about $16 billion to over $100 billion, as the company executed the acquisitions and formulary strategies that would define the modern PBM model.
Express Scripts pays $9.3 million to settle multistate drug-switching claims
Express Scripts entered a $9.5 million settlement with 28 states and the District of Columbia, paying $9.3 million to the states plus up to $200,000 in patient refunds, to resolve allegations that it did not clearly disclose details of its drug-switching programs and at times unfairly communicated the cost benefits of switching prescriptions. The company agreed to disclose to prescribers when manufacturers fund its switch promotions and clinical visits.
Data breach exposes up to 700,000 patient records
In October 2008 Express Scripts received an extortion letter containing the names, birth dates, Social Security numbers and prescription data of 75 patients; it refused to pay and notified the FBI. By September 2009 the company had notified about 700,000 members whose data may have been compromised, highlighting vulnerabilities in PBM data security.
Express Scripts completes $4.675 billion acquisition of WellPoint's NextRx
Express Scripts closed its $4.675 billion purchase of WellPoint's NextRx pharmacy benefit subsidiaries and signed a 10-year agreement to provide pharmacy benefit services, including home delivery and specialty pharmacy, to members of WellPoint's affiliated health plans. The deal absorbed another large PBM book of business into Express Scripts ahead of the Medco merger.
Express Scripts announces $29 billion Medco acquisition
Express Scripts announced a definitive agreement to acquire Medco Health Solutions, valuing Medco at $71.36 per share in cash and stock, or $29.1 billion, combining two of the three largest U.S. pharmacy benefit managers. FTC Commissioner Julie Brill would later dissent from the FTC's clearance, calling it a 'merger to duopoly.'
FTC approves Medco merger with 3-1 vote despite duopoly concerns
The FTC voted 3-1 to close its eight-month investigation and allow the Express Scripts-Medco merger to proceed without conditions. Commissioner Brill issued a dissent describing the deal as an industry 'game changer' creating a 'merger to duopoly' with CVS Caremark, 'with few efficiencies and high entry barriers.'
Express Scripts launches formulary exclusion program
Express Scripts dropped 48 brand-name drugs from its 2014 standard National Preferred Formulary, following CVS Caremark's lead in using outright formulary exclusions to extract larger price and rebate concessions from manufacturers. Patients taking excluded drugs had to switch medications or pay full price out of pocket.
Express Scripts cuts 400 more jobs after eliminating 1,890 in May
Express Scripts announced 400 layoffs at facilities around the country, including 90 in St. Louis, on top of 1,890 jobs cut system-wide in May 2014. The company cited lower prescription volumes and client losses, including UnitedHealth Group; a health management professor linked the cuts to streamlining after the Medco merger.
Accredo agrees to pay $60 million over Novartis kickback allegations
Accredo Health Group, the specialty pharmacy Express Scripts acquired with Medco, agreed to pay $60 million to the federal government and several states to resolve allegations that it recommended the drug Exjade to Medicaid patients in exchange for kickbacks from manufacturer Novartis.
DIR fee clawbacks begin escalating dramatically
By the mid-2010s, PBMs including Express Scripts had expanded Medicare Part D 'direct and indirect remuneration' (DIR) fees into a catch-all of network-participation charges and performance-based fees assessed months after prescriptions were dispensed, clawing back reimbursement retroactively. Pharmacies said opaque contract terms made it impossible to know their actual payment at the time of dispensing.
Anthem sues Express Scripts for $15 billion over drug pricing
Anthem, Express Scripts' largest client accounting for 18% of revenue, filed a $15 billion lawsuit alleging the PBM overcharged Anthem by roughly $3 billion annually and failed to pass along drugmaker discounts. The dispute stemmed from a 10-year pricing contract signed in 2009 when Express Scripts bought Anthem's in-house PBM for $4.7 billion.
Independent pharmacies sue Express Scripts, alleging it 'slammed' customers into mail order
Five independent pharmacies from four states filed a proposed class action in federal court in Missouri alleging Express Scripts used confidential prescription data to identify their most profitable customers and switch them into its mail-order business without the customers' permission, a practice they called 'slamming'. The pharmacies said they were then told the prescriptions had moved to mandatory mail order and only Express Scripts could fill refills. Express Scripts called the suit baseless; it was later dismissed and the dismissal upheld on appeal in 2020.
Cigna announces $67 billion Express Scripts acquisition
Cigna Corporation announced it would acquire Express Scripts in a $67 billion deal combining a major health insurer with the nation's largest PBM. The vertical integration would allow the combined entity to control insurance coverage, formulary decisions, claims processing, and pharmacy dispensing. Critics warned this created irreconcilable conflicts of interest.
Express Scripts closes Columbus pharmacy, lays off 456 workers
Express Scripts closed its Columbus, Ohio mail-order pharmacy facility, laying off 456 employees including 97 pharmacists, under a WARN Act notice filed April 10, 2018, about a month after Cigna announced its acquisition. Express Scripts said the work would move to other sites and that the closure was unrelated to the Cigna deal.
DOJ approves Cigna-Express Scripts vertical merger
The Department of Justice Antitrust Division approved the Cigna-Express Scripts merger, determining the vertical combination was 'unlikely to result in harm to competition or consumers.' The deal closed on December 20, 2018 at approximately $54 billion, with Cigna also assuming $15 billion in Express Scripts debt.
Anthem drops Express Scripts, costing $20 billion in annual revenue
Anthem announced it would end its Express Scripts contract on March 1, 2019, 10 months ahead of schedule, and move to its own PBM, IngenioRx. Anthem had been Express Scripts' largest client, worth roughly $20 billion in annual revenue and about $2.25 billion in 2016 EBITDA, and the split followed Anthem's lawsuit alleging Express Scripts overcharged it by roughly $3 billion per year.
Express Scripts and Cigna cap insulin copays at $25 with Patient Assurance Program
Cigna and Express Scripts launched the Patient Assurance Program, under which eligible people with diabetes in participating plans pay no more than $25 for a 30-day supply of insulin. The companies said it cut out-of-pocket insulin costs by 40% or more, on average, for many patients.
Express Scripts creates offshore GPO Ascent Health Services in Switzerland
Express Scripts launched Ascent Health Services, a Switzerland-based group purchasing organization that took over its rebate negotiations with drug manufacturers. Drug Channels identified likely motives as tax efficiency from Switzerland's lower corporate tax rate and using GPO safe harbor rules to sidestep rebate reform while collecting GPO administrative fees. The FTC's 2026 settlement would later require reshoring Ascent to the U.S.
Axios exposes Express Scripts pharmacy clawback practices
Axios reported on Express Scripts' systematic clawback practices, revealing how the PBM claws back millions of dollars per year from pharmacies after prescriptions are dispensed through 'quality' metrics and retroactive adjustments. Express Scripts managed pharmacy benefits for roughly 100 million people while maintaining opaque fee structures.
Express Scripts and Prime Therapeutics announce major collaboration
Express Scripts struck a three-year deal with Prime Therapeutics, collectively owned by 18 Blue Cross Blue Shield plans covering 28 million members. The partnership gave Express Scripts additional negotiating leverage over retail pharmacies and pharmaceutical manufacturers, further concentrating market power in drug supply chain negotiations.
Cigna reports CEO pay ratio of about 307:1 for 2019
Cigna's 2020 proxy statement, the first covering a full year with Express Scripts, reported CEO David Cordani's 2019 total compensation at $19.3 million against median employee pay of $62,946, a CEO pay ratio of about 307:1.
Appeals court upholds Express Scripts' right to move pharmacies' customers to its mail order
The Eighth Circuit affirmed dismissal of Trone Health Services v. Express Scripts, a suit by five independent network pharmacies alleging breach of contract and attempted monopolization. The pharmacies said Express Scripts used confidential customer data from their claims to switch their customers to its own mail-order pharmacy; the court held their network agreements permitted Express Scripts to fill those refills through its mail-order service.
Cigna rebrands Express Scripts unit as Evernorth
Cigna rebranded its health services segment, including Express Scripts, Accredo specialty pharmacy and eviCore, under the Evernorth brand, positioning the businesses as a one-stop shop for other payers, employers and government clients. Evernorth got about 90% of its business from clients outside Cigna. The rebrand did not include major immediate internal reorganization.
Court dismisses most of Anthem's $14.8 billion pricing claims against Express Scripts
In Anthem's 2016 lawsuit seeking more than $14.8 billion for pricing above competitive benchmarks, a federal judge in New York granted Express Scripts partial summary judgment, dismissing Anthem's declaratory judgment claim, its pricing breach-of-contract claim for failure to prove damages, and most operational claims. A claim over Express Scripts' prior authorization processes remained.
J&J sues SaveOnSP over copay maximizer run with Express Scripts and Accredo
Johnson & Johnson sued SaveOnSP, alleging that the copay maximizer, working with Express Scripts and its Accredo specialty pharmacy, exploited J&J's CarePath patient assistance program and caused J&J to pay at least $100 million more in copay assistance than it otherwise would have. Copay maximizers capture manufacturer assistance intended to lower patients' out-of-pocket costs for specialty drugs.
FTC orders Express Scripts and other large PBMs to turn over data in industry inquiry
The FTC launched a Section 6(b) inquiry into vertically integrated pharmacy benefit managers, sending compulsory orders to the six largest PBMs, including Express Scripts, to scrutinize their effect on the access and affordability of prescription drugs. The inquiry produced the 2024 and 2025 interim staff reports.
Whistleblower lawsuit alleges TRICARE 'refill pill mill' fraud
A qui tam lawsuit was unsealed alleging Express Scripts operated a 'refill pill mill' that systematically over-dispensed medications to TRICARE beneficiaries from 2009 to 2018. The company's system allegedly sent 90-day refills at the 60-day mark, dispensing 73% more pills than prescribed annually and defrauding the Department of Defense of billions in excess costs.
Nearly 15,000 pharmacies drop from TRICARE network over reimbursement
Approximately 14,963 retail pharmacies, mostly independents, left the Express Scripts-managed TRICARE network on October 24, 2022 after declining new contract terms that lowered reimbursement to levels they said would force them to operate at a loss. The change was estimated to affect about 400,000 TRICARE beneficiaries, who had to find other in-network pharmacies or use the TRICARE mail-order pharmacy run by Express Scripts.
TRICARE ends automatic mail-order refills without patient confirmation
Beginning in January 2023, TRICARE required mail-order pharmacy users to confirm each refill before Express Scripts shipped it, rather than sending refills automatically. Beneficiaries who declined or did not respond were removed from automatic refills.
Express Scripts president Adam Kautzner becomes chair of PBM lobby PCMA
The Pharmaceutical Care Management Association, the pharmacy benefit manager trade group that lobbies against PBM reform proposals, named Express Scripts president Adam Kautzner chairman of its board of directors.
Cigna reports 277:1 CEO pay ratio for 2022
Cigna's 2023 proxy statement reported CEO David Cordani's 2022 total compensation at $20,965,504 against median employee pay of $75,627, a CEO pay ratio of 277:1.
Ohio sues Express Scripts and Prime Therapeutics for collusion
Ohio Attorney General Dave Yost sued Express Scripts, Cigna, Evernorth, the Ascent Health Services GPO, Prime Therapeutics and Humana Pharmacy Solutions under Ohio's Valentine Act antitrust law, alleging they used Ascent to share pricing, discount and rebate information and collude to raise prescription drug costs. In a separate proceeding, an arbitrator ruled in January 2025 that Prime had engaged in a price-fixing collaboration with Express Scripts over pharmacy reimbursement, awarding the AIDS Healthcare Foundation about $10.3 million against Prime.
Pharmacies in Wisconsin, Minnesota and New Jersey sue Express Scripts over Prime collaboration
Four independent pharmacies, two in Wisconsin and one each in Minnesota and New Jersey, sued Express Scripts alleging its 2019 collaboration with Prime Therapeutics was an anticompetitive deal that let both PBMs charge pharmacies Express Scripts' higher transaction fees and pay its lower reimbursement rates. Prime was not named as a defendant, and Express Scripts called the suit baseless.
Cigna increases share repurchase authorization by $10 billion
After walking away from a potential Humana merger, Cigna's board approved a $10 billion increase to its share repurchase authorization, bringing total authority to $11.3 billion, and the company said it intended to buy back at least $5 billion of stock by the end of the first half of 2024.
Independent pharmacies sue Express Scripts over alleged price-fixing with rival PBMs
A proposed class action brought by Berger Montague on behalf of independent pharmacies alleged that Express Scripts used its dominant position to have rival PBMs, including Prime Therapeutics, impose its low reimbursement rates and high back-end fees on pharmacies, and then shared in the resulting revenue.
Cigna announces $3.2 billion accelerated stock repurchase
The Cigna Group announced a $3.2 billion accelerated stock repurchase agreement, part of a plan to buy back at least $5 billion in stock during the first half of 2024. The company would ultimately repurchase approximately $7 billion in shares during 2024 while Express Scripts' parent simultaneously pursued cost-cutting initiatives.
Federal auditor finds Express Scripts overcharged postal workers' plan by $44.9 million
The Office of Personnel Management's inspector general found Express Scripts overcharged the American Postal Workers Union Health Plan and the Federal Employees Health Benefits Program by nearly $44.9 million in 2016-2021 by not passing through required discounts and credits. Findings included about $14.4 million in retail pass-through pricing, $5.3 million in manufacturer rebates, and about $15.8 million in rebates withheld by Express Scripts' sister GPO Ascent Health Services in 2019 and 2020.
FTC interim report finds top 3 PBMs control 80% of prescriptions
The FTC released its first interim PBM report finding that Express Scripts, CVS Caremark, and OptumRx process nearly 80% of all U.S. prescriptions and that their affiliated pharmacies capture nearly 70% of all specialty drug revenue. The report documented how PBMs use market dominance to inflate drug prices and impose unfair terms on independent pharmacies.
Express Scripts sues FTC over PBM report
Express Scripts sued the FTC and its chair, Lina Khan, in federal court, calling the agency's July 2024 interim report on PBM practices 'unfair, biased, erroneous, and defamatory' and seeking its retraction and Khan's recusal from matters involving the company. The legal challenge signaled the company's combative posture toward regulatory oversight.
FTC sues Express Scripts and two other PBMs over insulin prices
The Federal Trade Commission filed an administrative action against Express Scripts, CVS Caremark, OptumRx, and their affiliated GPOs, alleging anticompetitive rebating practices that artificially inflated insulin drug list prices. The FTC found that PBMs pressured insulin manufacturers to compete on rebate size rather than net price, keeping a slice of inflated rebates while patients paid more at the pharmacy counter.
Kentucky sues Express Scripts for role in opioid crisis
Kentucky Attorney General Russell Coleman filed suit against Express Scripts alleging the PBM conspired with opioid manufacturers to manipulate public perception of opioid safety, secured favorable formulary placement for opioids in exchange for rebates, eliminated prior authorization safeguards, and ignored patterns of widespread abuse. West Virginia filed a parallel suit in August 2025.
Express Scripts sues FTC, challenging constitutionality of insulin case
Express Scripts, along with Caremark and OptumRx, filed a complaint in the U.S. District Court for the Eastern District of Missouri alleging that the FTC's administrative proceeding over insulin pricing violated the Constitution, and sought a preliminary injunction to halt it. Express Scripts' own challenge ended when it agreed to settle with the FTC in February 2026.
FTC second interim report reveals $7.3 billion in specialty drug markups
The FTC's second interim PBM staff report found that the three largest PBMs imposed markups of hundreds to thousands of percent on specialty generic drugs used to treat cancer, HIV, and other serious conditions, yielding over $7.3 billion in excess revenue between 2017 and 2022. PBMs earned an additional $1.4 billion in spread pricing on these drugs.
J&J adds Express Scripts and Accredo as defendants in copay maximizer suit
More than two and a half years after suing SaveOnSP, Johnson & Johnson moved to add Express Scripts and Accredo as defendants, claiming the copay maximizer scheme the companies operated together was siphoning off tens of millions of dollars from its patient assistance program.
Arbitrator finds Prime engaged in price-fixing with Express Scripts
An arbitrator awarded the AIDS Healthcare Foundation more than $10 million and injunctive relief after finding that Prime Therapeutics engaged in horizontal price-fixing with Express Scripts through their pharmacy reimbursement collaboration. Prime was ordered to end the reimbursement structure it used under the collaboration.
Cigna adds $6 billion in buyback authority after repurchasing $7 billion in 2024
Reporting 2024 results, Cigna said it repurchased 20.9 million shares for about $7.0 billion during the year and its board approved another $6.0 billion in share repurchase authorization, bringing total authority to $10.3 billion.
Ninth Circuit revives TRICARE auto-refill fraud suit against Express Scripts
The Ninth Circuit reversed the dismissal of a False Claims Act suit alleging Express Scripts over-dispensed medication to TRICARE beneficiaries through its automatic refill program, holding that earlier public sources did not trigger the Act's public-disclosure bar, and returned the case to the district court.
Court lets pharmacies' price-fixing class action against Express Scripts proceed
A federal court in Washington state rejected Express Scripts' arguments that the pharmacies' collusion case had to be litigated in Missouri, could not proceed as a class action, and lacked a plausible antitrust claim, allowing the price-fixing theory against Express Scripts to go forward.
Cigna reports CEO Cordani's 2024 pay at $23.3 million, a 279:1 ratio
Cigna's 2025 proxy statement reported CEO David Cordani's 2024 total compensation at $23,251,096 against median employee pay of $83,483, a CEO pay ratio of 279:1, in a year the company repurchased about $7 billion of stock.
Michigan AG sues Express Scripts for pharmacy price-fixing conspiracy
Michigan Attorney General Dana Nessel filed an antitrust lawsuit against Express Scripts and Prime Therapeutics, alleging a long-running conspiracy to fix pharmacy reimbursement rates, eliminate competition in the retail pharmacy services market, and drive independent pharmacies out of business. The suit alleged Express Scripts controlled nearly 90% of the Michigan PBM market.
Research finds Cigna's private-label drugs flow almost exclusively through Express Scripts pharmacies
46brooklyn Research reported that products from Quallent, Cigna's Cayman Islands-domiciled private-label drug affiliate, were dispensed by Express Scripts or Accredo in all but one of more than 34,000 commercial claims reviewed, and that 51% of 2023 West Virginia commercial omeprazole claims priced at more than 20 times NADAC were Quallent products dispensed by Express Scripts. It also cited an Express Scripts plan document requiring specialty drugs to be filled at Accredo to be covered.
Court blocks Arkansas ban on PBM-owned pharmacies in suit led by Express Scripts
A federal court preliminarily enjoined Arkansas Act 624, the first state law barring PBMs from owning or operating pharmacies, in lawsuits whose lead plaintiffs included Express Scripts, Optum, CVS and PCMA. The court found the law likely violates the Commerce Clause and is likely preempted by TRICARE; Arkansas appealed to the Eighth Circuit.
West Virginia attorney general sues Express Scripts over opioid crisis role
West Virginia Attorney General JB McCuskey sued Express Scripts (now Evernorth Health) and related entities, alleging the PBM contributed to the oversupply of opioids in the state through its formulary placements while ignoring its own data on addiction risks.
PCMA names Express Scripts executive as board chair
The Pharmaceutical Care Management Association named Adam Kautzner, president of Express Scripts, as chair of its board, succeeding Prime Therapeutics CEO Mostafa Kamal. As chair, Kautzner oversees PCMA's strategy, including its defense of PBMs amid growing scrutiny. PCMA spent more than $17.5 million on lobbying in 2024, according to OpenSecrets.
Express Scripts announces shift to a rebate-free pharmacy benefit model
Cigna's Evernorth said Express Scripts would move to a pass-through model with discounts applied at the point of sale, adopted for Cigna's fully insured plans in 2027 and made the standard offering for all Express Scripts clients in 2028. It also said it would reimburse pharmacies on a cost-plus basis, rolling out across its network beginning in 2026, and estimated members would save an average of 30% a month on brand-name drugs.
Philadelphia sues Express Scripts over opioid crisis role
The City of Philadelphia filed a lawsuit against Express Scripts, CVS Caremark, and OptumRx alleging PBMs conspired with opioid manufacturers to increase prescribing and dispensing of opioids through favorable formulary placement in exchange for rebates. More than 12,000 people died of overdoses in Philadelphia between 2010 and 2023. The suit invoked RICO statutes.
Express Scripts home delivery stops filling prescriptions under 35 days for Highmark members
Highmark notified providers that, effective Jan. 1, 2026, Express Scripts Pharmacy home delivery would require at least a 35-day supply for most medications for members of its commercial, Medicare and ACA plans; shorter prescriptions must be reissued for a longer supply or sent to a retail pharmacy.
Express Scripts more than doubles formulary exclusions for 2026
Express Scripts' 2026 National Preferred Formulary added 48 exclusions effective Jan. 1, 2026, more than double the 21 changes a year earlier, including Symbicort, Vyvanse, Humalog vials and OneTouch diabetes supplies. Thirteen specialty exclusions followed biosimilar shifts, with brand Stelara excluded for all users from July 1, 2026 (PSG analysis).
FTC secures landmark settlement with Express Scripts
Express Scripts settled the FTC's insulin case without admitting wrongdoing or paying a penalty. Under the proposed consent order it agreed to stop preferring high-list-price versions of a drug over identical low-list-price versions on its standard formularies; offer plan sponsors a standard option basing members' out-of-pocket costs on net drug cost, delinking its manufacturer compensation from list prices and letting plans move off rebate guarantees and spread pricing; extend Patient Assurance Program insulin benefits to all members unless a plan opts out; move community pharmacies to a standard acquisition-cost-plus-fee model; add drug-level reporting and broker-payment disclosure; and reshore its Ascent GPO from Switzerland. The FTC voted 1-0 to accept it for public comment; most terms phase in by 2027-2028.
Cigna cuts 2,000 jobs while executing billions in buybacks
The Cigna Group moved to eliminate approximately 2,000 positions, just under 3% of its workforce, by the end of February, days after reporting 2025 revenue of $274.9 billion and net income of $6.0 billion. Cigna had reported a global workforce of about 73,500 at the end of 2024 in its annual report. Cigna had repurchased about $7 billion of its stock in 2024 and $3.6 billion in 2025.
Plan sponsors file racketeering class action over Express Scripts' Swiss GPO
Bernstein Litowitz Berger & Grossmann filed a class action on behalf of Express Scripts' PBM customers, led by the Plumbers' Welfare Fund of Chicago's Plumbers Local 130, alleging Express Scripts, Cigna and Evernorth diverted billions of dollars in manufacturer payments through Ascent, their Swiss group purchasing organization, by labeling them fees rather than rebates that contracts required sharing with clients.
Cigna names Brian Evanko to succeed David Cordani as CEO
Cigna announced that David Cordani would retire as CEO on July 1, 2026, after nearly 17 years and become executive chair, with president and COO Brian Evanko, who oversaw both Cigna Healthcare and Evernorth, succeeding him.
PBM lobby PCMA urges Labor Department to rescind PBM transparency rule
The Pharmaceutical Care Management Association, whose board Express Scripts president Adam Kautzner was named to chair in October 2025, urged the Labor Department to roll back a proposed rule requiring PBMs to disclose rebates and drugmaker payments to employers and plan sponsors, arguing it duplicated reforms Congress passed in February 2026.
Appeals court grants Express Scripts a jury in West Virginia opioid suit
The Fourth Circuit overturned a lower court's denial of a jury trial in a suit by 120 West Virginia local governments alleging Express Scripts contributed to the oversupply of opioids, siding with the PBM's demand for a jury.
Express Scripts sues to block Tennessee law barring PBMs from owning pharmacies
Express Scripts filed a federal lawsuit challenging Tennessee's FAIR Rx Act, which prohibits PBMs from owning pharmacies in the state, arguing it is unconstitutional and preempted by federal law. It was the second major PBM to sue after CVS Caremark; PCMA filed a separate suit.
Senators question Express Scripts' dual role in TRICARE pharmacy program
At a Senate Armed Services Committee hearing, Sen. Elizabeth Warren called Express Scripts' role as both TRICARE pharmacy benefit manager and owner of competing mail-order and specialty pharmacies a conflict of interest, and cited a 2022 network contract giving it rights to offset pharmacy payments after claims were processed. The committee's defense bill included a GAO audit of how Express Scripts reimburses its own pharmacies and competitors.
Cigna slows share buybacks to about $250 million in 2026
Cigna reported repurchasing about $250 million of stock in 2026 through July 29, down from about $3.6 billion in 2025 and $7.0 billion in 2024, while second-quarter shareholders' net income rose to $1.7 billion. Pharmacy Benefit Services pretax adjusted income fell 27%, which Cigna attributed to client initiatives including large contract renewals, while Specialty and Care Services grew 22%.
Florida attorney general sues Express Scripts and Prime over price-fixing
Florida Attorney General James Uthmeier sued Prime Therapeutics and Express Scripts, alleging their December 2019 collaboration was a horizontal price-fixing agreement under which Prime adopted Express Scripts' lower pharmacy reimbursement rates from April 2020. Prime's rates had been about 20% higher, and the suit says reimbursement fell for about 80% of branded and 70% of generic drugs.
Louisiana attorney general sues Express Scripts and Ascent
Louisiana Attorney General Liz Murrill sued Express Scripts and its GPO affiliate Ascent Health Services, alleging they used market power to manipulate pharmacy reimbursement, conceal profits and steer patients to pharmacies Express Scripts owns, and coordinated reimbursement rates and fees with competitor Prime Therapeutics.
Arkansas pharmacies sue Express Scripts over 48,300 below-cost reimbursements
Twelve independent Arkansas pharmacies sued Express Scripts in Missouri state court, the first suit under a 2025 Arkansas law letting pharmacies sue PBMs, alleging it paid below the NADAC acquisition-cost floor on roughly 48,300 prescriptions between August 2025 and March 2026 as a deliberate business decision. Express Scripts said it would defend itself.
Sixth Circuit lets Express Scripts move Kentucky opioid suit to federal court
The Sixth Circuit reversed a remand order and held that Express Scripts and OptumRx properly removed Kentucky's opioid lawsuit to federal court under the federal officer removal statute, following its January 2026 ruling keeping Ohio's antitrust suit against Express Scripts' Ascent GPO in federal court.
Evidence (52 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (9 entries)
Checked 2 alternatives, added 1. Cost Plus Drugs: removed false 'no specialty or brand-name drugs' claim, corrected fee structure. GoodRx: stripped typed-in score, added sourced caveats (FTC data penalty, Express Scripts partnership, pharmacy price-fixing suits). Added Navitus as the plan-sponsor option (pass-through PBM, SSM Health/Costco-owned) since patients cannot pick their PBM.
Checked 15 removed/trimmed claims: 0 restored, 6 partly restored, 9 confirmed removed. Partly restored: 2007 mail-order/slamming item re-added as 2016-08-08 slamming suit (Drug Topics; 2007 mandatory-mail expansion unsupported); Ohio item's Oct 2023 WI/MN/NJ pharmacy suit added as its own event (Fierce Healthcare 2023-10-24); PCMA 'opposing transparency' narrowed to March 2026 DOL-rule opposition (Fierce Healthcare 2026-03-20); Ascent GPO safe-harbor motive (Drug Channels); Cigna 73,500 workforce (FY2024 10-K); rebate-contract opacity evidence (KFF 2026-02-09). Confirmed removed: 800+ Anthem layoffs (forum only), 2020 regulatory-gap item (dead DOI), Nov 2024 Accredo mandate expansion, '79 pharmacies' (Encyclopedia says nearly 90), with the Cigna item's $9-10B annual buybacks (contradicted), KFF vertical-integration, USC Schaeffer margins, Pharmacy Times Accredo and Glassdoor evidence, and NCSL 'over 30 states' (unsupported; a Kutak Rock note says 26 states enacted PBM laws in 2025 but its page fails the link checker).
Checked 86 items + prose. 21 verified, 24 corrected (7 date-only), 28 re-sourced, 13 removed (1 duplicate, others unsourced/fabricated). Many evidence URLs were fabricated 404s with no archive. Invented: 'Pharmacy Care Value' program; '10-20x' spread/markup figure; 800+ Anthem-related layoffs (forum-only); Nov 2024 Accredo mandate expansion; 2023 Cigna 2,000-job cut with IT outsourcing (misdated duplicate of Feb 2026); workers' synergy-cuts quote in Columbus closure; nonexistent Health Affairs articles (timeline[22], evidence[16]); nonexistent USC study (evidence[17]). Fixed: $9-10B buyback claims, buyback date (Dec 2023 not 2024), PCMA chair date (Oct 2025) and lobbying figure ($17.5M, +14%), multistate settlement (28 states + DC, May 2008), NY Spitzer outcome ($27M), FTC suit dates (Sept 17 and Nov 19, 2024), Ohio suit and AHF arbitration dates, TRICARE mail order (not Accredo), market share in description. [Amended by regrade 2026-09-25: FTC settlement timeline event (and several narratives) still said the order eliminates spread pricing and passes rebates to patients by 2028; the FTC release says plans get an option to drop spread pricing and a net-cost standard benefit. Rewrote the event description and narratives.]
Since Feb 2026: FTC settlement (Feb 4; order still not final Sept 2026), Cigna 2,000 layoffs, RICO class action over Ascent (Feb 17), CEO handover Cordani->Evanko (Jul 1), buybacks cut to ~$250M YTD, Express Scripts sued Tennessee over PBM-pharmacy ownership ban (Jun 12), Senate scrutiny of TRICARE role (Jul 15), Florida and Louisiana AG price-fixing suits (Aug 27/31), Arkansas pharmacies' 48,300-claim below-NADAC suit (Sep 15), 6th Cir removal win in Kentucky opioid case (Sep 18); late 2025 rebate-free model announced and 2026 exclusions doubled to 48. 74->71. D1 8->7 (recalibration: annual exclusions, PA and list-price-based cost sharing fit 7, not 'shadow of former self'; insulin cap and point-of-sale pricing offset). D3 8->7 (correction: fact audit cut $9-10B/yr buyback claims to $7.0B/2024 and $3.6B/2025; 2026 buybacks ~$250M). D5 9->8 (recalibration: deliberate opacity fits 8; no falsified metrics, pass-through options and settlement reporting exist). D6 7->6 (correction: fact audit removed fabricated D6 evidence, the 2007 mandatory mail-order and 2024 Accredo-mandate events; remaining record is steering, copay maximizer and auto-refill allegations). D9 7->6 (correction: fact audit removed 800+ Anthem layoffs and Glassdoor claims; record is layoffs amid buybacks and 279-310:1 pay ratios, no anti-union or retaliation evidence). D10 5->7 (event: sued Tennessee Jun 2026 and led the Arkansas Act 624 challenge, repeated federal removal of state suits, on top of two suits against the FTC; fits 'strategic litigation to delay regulation'). D2, D4, D7, D8 unchanged. Eras: Consolidation Wave re-dated 1999-01-01->1998-04-01 (ValueRx); Post-Medco re-dated 2012-04-01->2012-04-02; Cigna era re-dated 2018-12-01->2018-12-20 (closing); 'Peak Extraction' re-dated 2022-01-01->2022-10-24 and relabeled 'TRICARE Network Squeeze'; FTC Enforcement re-dated 2024-09-01->2024-09-20; current 'Forced Reform' re-dated 2026-02-15->2026-02-04 (settlement); Startup PBM kept. Timeline: fixed FTC-settlement description (spread pricing is an option, not eliminated); PCMA event moved from D9 to D10. Trajectory worsening->stable.
Triaged 2026-06-29; no rescore warranted (no material change since baseline, or changes sub-threshold).
Corrected D3/D9 layoff timing from 2024 to early 2026 (Cigna-wide, not Express Scripts-specific). Fixed CEO Cordani compensation from 'over $25M' to $23.3M (2024). Updated PCMA lobbying from $17.5M to ~$18M (up 20%, not 14%). Fixed 3 fabricated FTC evidence URLs to correct paths. Replaced 2 fabricated Fierce Healthcare/Modern Healthcare evidence URLs with verified sources. Fixed history entry format (removed non-standard event field, added source: current).